Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 28, 2008

Alticor Backs Interleukin Genetics Risk Assessment Research

  • Interleukin Genetics and Access Business Group (ABG) are collaborating to conduct genetic risk assessment studies. The firms will focus on osteoporosis, cardiovascular disease, nutrigenomics, and dermagenomics.

    ABG will pay $1.2 million during this year for the research, which Interleukin Genetics will conduct. Approximately $800,000 of unspent funding from prior research agreements with ABG shall also be credited against the costs incurred under this new agreement.

    Studies aim at correlating SNPs to the risk of osteoporosis and cardiovascular disease in Asian populations. The partners will also seek to identify genetic factors that influence athletic performance and skin appearance.

    Interleukin Genetics reports that previous agreements with Alticor led to the commercial launch in March 2006 of a genetic test for  early heart disease risk, a nutritional supplement beneficial for those who test positive for the genetic risk factor identified by this test, and a general nutrition test panel.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »